Literature DB >> 24162261

Automated objective determination of percentage of malignant nuclei for mutation testing.

Hollis Viray1, Madeline Coulter, Kevin Li, Kristin Lane, Aruna Madan, Kisha Mitchell, Kurt Schalper, Clifford Hoyt, David L Rimm.   

Abstract

Detection of DNA mutations in tumor tissue can be a critical companion diagnostic test before prescription of a targeted therapy. Each method for detection of these mutations is associated with an analytic sensitivity that is a function of the percentage of tumor cells present in the specimen. Currently, tumor cell percentage is visually estimated resulting in an ordinal and highly variant result for a biologically continuous variable. We proposed that this aspect of DNA mutation testing could be standardized by developing a computer algorithm capable of accurately determining the percentage of malignant nuclei in an image of a hematoxylin and eosin-stained tissue. Using inForm software, we developed an algorithm, to calculate the percentage of malignant cells in histologic specimens of colon adenocarcinoma. A criterion standard was established by manually counting malignant and benign nuclei. Three pathologists also estimated the percentage of malignant nuclei in each image. Algorithm #9 had a median deviation from the criterion standard of 5.4% on the training set and 6.2% on the validation set. Compared with pathologist estimation, Algorithm #9 showed a similar ability to determine percentage of malignant nuclei. This method represents a potential future tool to assist in determining the percent of malignant nuclei present in a tissue section. Further validation of this algorithm or an improved algorithm may have value to more accurately assess percentage of malignant cells for companion diagnostic mutation testing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24162261      PMCID: PMC3999345          DOI: 10.1097/PAI.0b013e318299a1f6

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  25 in total

1.  Systematic analysis of breast cancer morphology uncovers stromal features associated with survival.

Authors:  Andrew H Beck; Ankur R Sangoi; Samuel Leung; Robert J Marinelli; Torsten O Nielsen; Marc J van de Vijver; Robert B West; Matt van de Rijn; Daphne Koller
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

2.  Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Authors:  Aude Lamy; France Blanchard; Florence Le Pessot; Richard Sesboüé; Frédéric Di Fiore; Jessie Bossut; Elodie Fiant; Thierry Frébourg; Jean-Christophe Sabourin
Journal:  Mod Pathol       Date:  2011-04-22       Impact factor: 7.842

3.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

Authors:  Athanasios C Tsiatis; Alexis Norris-Kirby; Roy G Rich; Michael J Hafez; Christopher D Gocke; James R Eshleman; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

4.  Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.

Authors:  Suzanne Kamel-Reid; Tong Zhang; Diane L Persons; Marina N Nikiforova; Kevin C Halling
Journal:  Arch Pathol Lab Med       Date:  2012-01       Impact factor: 5.534

5.  Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Authors:  Arne Warth; Roland Penzel; Regine Brandt; Christine Sers; Jürgen R Fischer; Michael Thomas; Felix J F Herth; Manfred Dietel; Peter Schirmacher; Hendrik Bläker
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

6.  Comparison of KRAS mutation tests in colorectal cancer patients.

Authors:  Veysel Sabri Hancer; Murat Buyukdogan; Ilknur Türkmen; Nuray Bassullu; Tuncay Altug; Reyhan Diz-Kucukkaya; Gulen Bulbul-Dogusoy; Gokhan Demir
Journal:  Genet Test Mol Biomarkers       Date:  2011-06-23

7.  Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.

Authors:  Pietro Carotenuto; Cristin Roma; Salvatore Cozzolino; Francesca Fenizia; Anna Maria Rachiglio; Fabiana Tatangelo; Alessia Iannaccone; Luigi Baron; Gerardo Botti; Nicola Normanno
Journal:  Int J Oncol       Date:  2011-10-04       Impact factor: 5.650

8.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

9.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Authors:  S Fasanella; E Leonardi; C Cantaloni; C Eccher; I Bazzanella; D Aldovini; E Bragantini; L Morelli; L V Cuorvo; A Ferro; F Gasperetti; G Berlanda; P Dalla Palma; M Barbareschi
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

View more
  6 in total

1.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

2.  Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.

Authors:  K A Rejniak; M C Lloyd; D R Reed; M M Bui
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

3.  Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.

Authors:  Matthew D Hellmann; Justin Gainor; Kurt A Schalper; Miguel Lopez de Rodas; Venkata Nagineni; Arvind Ravi; Ila J Datar; Mari Mino-Kenudson; German Corredor; Cristian Barrera; Lindsey Behlman; David L Rimm; Roy S Herbst; Anant Madabhushi; Jonathan W Riess; Vamsidhar Velcheti
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 4.  Translational AI and Deep Learning in Diagnostic Pathology.

Authors:  Ahmed Serag; Adrian Ion-Margineanu; Hammad Qureshi; Ryan McMillan; Marie-Judith Saint Martin; Jim Diamond; Paul O'Reilly; Peter Hamilton
Journal:  Front Med (Lausanne)       Date:  2019-10-01

5.  Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study.

Authors:  Mustafa Umit Oner; Jianbin Chen; Egor Revkov; Anne James; Seow Ye Heng; Arife Neslihan Kaya; Jacob Josiah Santiago Alvarez; Angela Takano; Xin Min Cheng; Tony Kiat Hon Lim; Daniel Shao Weng Tan; Weiwei Zhai; Anders Jacobsen Skanderup; Wing-Kin Sung; Hwee Kuan Lee
Journal:  Patterns (N Y)       Date:  2021-12-09

6.  Artificial intelligence-augmented histopathologic review using image analysis to optimize DNA yield from formalin-fixed paraffin-embedded slides.

Authors:  Bolesław L Osinski; Aïcha BenTaieb; Irvin Ho; Ryan D Jones; Rohan P Joshi; Andrew Westley; Michael Carlson; Caleb Willis; Luke Schleicher; Brett M Mahon; Martin C Stumpe
Journal:  Mod Pathol       Date:  2022-10-05       Impact factor: 8.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.